Home 
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.11, p.819–826, 2019
Bratislava Medical Journal 2019 Bratislava Medical Journal Vol.120, No.11, p.819–826, 2019
Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.120, No.11, p.819–826, 2019 |
||
| Title: IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia | ||
| Author: G. Guney Eskiler, E. Bezdegumeli, Z. Ozman, A. Deveci Ozkan, C. Bilir, B. N. Kucukakca, M. N. Ince, A. Y. Men, O. Aktas, Y. E. Horoz, D. Akpinar, I. Genc, S. Kaleli | ||
| Abstract: OBJECTIVES: We investigated the changes in the IL-6 and STAT3 expression levels in cachectic and non-cachectic patients with gastric, lung and breast cancer and evaluated the association between IL-6 and STAT3 levels and cancer types in terms of cachexia condition. BACKGROUND: Cancer-associated cachexia, observed in nearly 50‒80 % of cancer patients, has drawn attention in advanced patients. IL-6/JAK/STAT pathway plays an essential role in the progression of cancer cachexia through the regulation of the inflammatory response. METHODS: This study consisted of 48 gastric, breast and lung cancer patients (18 cachectic and 30 non-cachectic) and healthy individuals. Total RNA isolation and cDNA synthesis was performed after the collection of blood samples. IL-6 and STAT3 expression levels were analyzed by RT- PCR analysis. RESULTS: Our findings demonstrated that IL-6 mRNA levels considerably increased 19.89±8.25, 5.18±2.81 and 15.33±9.54-fold in gastric, lung and breast cancer patients with cachexia, respectively. Additionally, a 16.67±7.13, 14.21±11.72 and 8.85±3.89-fold increase in the STAT3 expression level was detected in cachectic gastric, lung and breast cancer patients, respectively (p<0.01). CONCLUSION: STAT3 may be considered as a therapeutic target for cachectic patients with gastric, lung and breast cancer. Furthermore, IL-6 mediates STAT3 activation in cachectic gastric and breast cancer patients (Tab. 5, Fig. 2, Ref. 62). |
||
| Keywords: cachexia, IL-6, STAT3, gastric cancer, lung cancer, breast cancer | ||
| Published online: 20-Nov-2019 | ||
| Year: 2019, Volume: 66, Issue: 11 | Page From: 819, Page To: 826 | |
| doi:10.4149/BLL_2019_136 |
||
|
|
 download file |
|